[HTML][HTML] Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer …
Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …
treatment options have improved outcomes in advanced prostate cancer. However, we still …
Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …
making it an excellent target for imaging and treating patients with prostate cancer. Several …
[HTML][HTML] 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a
therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be …
therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be …
Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery
RP Coll, SJ Bright, DKJ Martinus, DK Georgiou… - Molecular Imaging and …, 2023 - Springer
Critical advances in radionuclide therapy have led to encouraging new options for cancer
treatment through the pairing of clinically useful radiation-emitting radionuclides and …
treatment through the pairing of clinically useful radiation-emitting radionuclides and …
¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a
therapeutic target. Lutetium-177 (¹⁷⁷Lu)-PSMA-617 is the first radioligand therapy to be …
therapeutic target. Lutetium-177 (¹⁷⁷Lu)-PSMA-617 is the first radioligand therapy to be …
Novel treatment strategies to overcome resistance in prostate cancer
V Fernandez, Y Mirzabeigi, AM Joseph, M Karas… - Therapy Resistance in …, 2024 - Elsevier
Prostate cancer (PCa) is typically treated by inhibiting androgen receptor (AR) signaling
through surgical or medical castration. Although this therapy can result in absolute remission …
through surgical or medical castration. Although this therapy can result in absolute remission …
[PDF][PDF] Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
MS Hofman - 2022 - acmn.com.co
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …
making it an excellent target for imaging and treating patients with prostate cancer. Several …
Sequential and Combination Therapies of 223 RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy
H Jadvar - 2023 - Soc Nuclear Med
There have been unprecedented strides in theranostics, facilitating the bidirectional “see
and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate …
and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate …
[HTML][HTML] Theranostics in prostaatkanker
BM Privé, CHJ Muselaers, SMB Peters… - Tijdschrift voor …, 2024 - Springer
In de afgelopen jaren wordt de term 'theranostics' steeds vaker gebruikt. Een nieuwe, reeds
welbekende, theranostic of radioligand-therapie (RLT) is 177Lu-PSMA, waarmee patiënten …
welbekende, theranostic of radioligand-therapie (RLT) is 177Lu-PSMA, waarmee patiënten …
[HTML][HTML] Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database
MS Fontes, FA Schutz, M de Almeida Luz… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Background With the ongoing expansion of life-prolonging therapies approved to treat
advanced prostate cancer, there is currently an unmet need to better understand real-world …
advanced prostate cancer, there is currently an unmet need to better understand real-world …